Related Experiment Video
Updated: May 14, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome
Alejandro Balestracci1, Sandra Mariel Martin, Ismael Toledo
1Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Ciudad Autónoma de Buenos Aires, Argentina. abalestracci@yahoo.com.ar
Insights
Platelet transfusions in children with post-diarrheal hemolytic uremic syndrome (D+HUS) did not worsen disease outcomes. No increased complications were observed, suggesting careful individual assessment of transfusion benefits and risks is warranted.
Area of Science:
- Pediatrics
- Hematology
- Nephrology
Background:
- Post-diarrheal hemolytic uremic syndrome (D+HUS) is a serious condition in children.
- Platelet transfusions are often avoided in D+HUS due to concerns about worsening microthrombi formation.
Purpose of the Study:
- To investigate the impact of platelet transfusions on the disease course of children with D+HUS.
- To compare outcomes between D+HUS patients who received platelet transfusions and those who did not.
Main Methods:
- Retrospective case-control study.
- Compared outcomes in 23 children with D+HUS who received platelet transfusions versus 54 who did not.
Main Results:
- No significant differences were observed between the groups in terms of age, gender, weight, height, prior medication use, or dehydration at admission.
- Key clinical parameters including initial laboratory values, dialysis duration, need for erythrocyte transfusions, peak creatinine, severity of organ injury (bowel, neurologic), arterial hypertension, intensive care unit admission, and mortality were comparable between groups.
- No hemorrhagic complications were noted in the non-transfused group.
Conclusions:
- Platelet transfusion does not appear to aggravate the disease course in children with D+HUS.
- Further studies are needed to confirm these findings.
- The benefits and risks of platelet transfusion should be carefully weighed on a case-by-case basis for D+HUS patients.
Background:
Platelet transfusions should be avoided in children with post-diarrheal hemolytic uremic syndrome (D + HUS) because they might increase microthrombi formation, thereby aggravating the disease. As this possibility has not yet been explored, we investigated whether platelet transfusion in patients with D + HUS would lead to a worse disease course compared to that in patients who did not receive platelet transfusion.
Methods:
This was a case-control study in which data from D + HUS children who received platelet transfusions (cases, n = 23) and those who did not (controls, n = 54) were retrospectively reviewed and compared.
Results:
Both patient groups were similar in age (p = 0.3), gender (p = 0.53), weight (p = 0.86), height (p = 0.45), prior use of non-steroidal anti-inflammatory drugs (p = 0.59) or antibiotics (p = 0.45) and presence of dehydration at admission (p = 0.79). The two groups also did not differ in initial leukocyte count (p = 0.98), hematocrit (p = 0.44) and sodium (p = 0.11) and alanine aminotransferase levels (p = 0.11). During hospitalization, dialysis duration (p = 0.08), number of erythrocyte transfusions (p = 0.2), serum creatinine peak (p = 0.22), presence of severe bowel (p = 0.43) or neurologic (p = 0.97) injury, arterial hypertension (p = 0.71), need for intensive care (p = 0.33) and death (p = 1.00) were also comparable.
Conclusion:
Our findings suggest that platelet transfusion does not aggravate the course of the disease. Conversely, no hemorrhagic complications were observed in the group of patients who did not receive a platelet transfusion. Until these observations are confirmed by further studies, the benefits and risk of platelet transfusion should be thoughtfully balanced on an individual case basis.
